In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Raven Biotechnologies Inc.

Division of MacroGenics Inc.

Latest From Raven Biotechnologies Inc.

Deals Of The Week: Will Pharmasset’s Windfall Lead To Similar Exits For Other Hepatitis C Biotechs?

Almost two weeks later, people are still talking about ramifications from Gilead’s $11 billion buyout of Pharmasset, but companies such as Roche, Elan and Curis have been active deal makers in recent days.

BioPharmaceutical Europe

Servier, MacroGenics Forge Option Deal For Cancer Drug

The French pharma acquires the right to license the antibody MGA271, which has received strong interest since BMS’s Yervoy was approved in March.

BioPharmaceutical Europe

The State of Investing in Antibody Technology

Since December 2001, only two privately held antibody firms have raised more than $15 million in a round of financing. Moreover, the older public companies founded on the promise of disruptive antibody development technologies, principally Abgenix and Medarex with fully human antibodies, and Human Genome Sciences with its antibody-driven genomics discovery science, have yet to validate those platforms through successful clinical product development. Even antibody humanization specialist Protein Design Labs, which has marketed antibody products from which it's getting royalties, is still selling for not much more than its cash value. Yet despite a fall-off in investments in this core area of biotech drug development, VCs still say antibodies will provide a range of successful new therapies.
BioPharmaceutical Strategy

When is a Target Not a Target?

Medarex is reevaluating its plans to bring 10 antibodies into the clinic each year, in part because targets identified by its array of young partners are taking a lot of work to validate. The company has gained appreciation for vaccines and for the potential of using antibodies as general immune stimulants rather than specifically targeted therapeutics.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MacroGenics Inc.
  • Senior Management
  • George F Schreiner, MD, PhD, CEO
    Jennie P Mather, PhD, Pres. & CSO
  • Contact Info
  • Raven Biotechnologies Inc.
    Phone: (650) 624-2600
    One Corporate Dr.
    S. San Francisco, CA 94080